You are here

Article info

Article menu
Download PDFPDF
Case report
Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia

Authors

  1. Correspondence to Dr Pamela Elena Baez-Islas; drabaez.hematologia{at}gmail.com
View Full Text

Citation

Ovilla-Martinez R, Weber Sánchez LA, Cota-Rangel X, et al
Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia
BMJ Case Reports CP 2021;14:e243745.

Publication history

  • Accepted October 19, 2021
  • First published November 11, 2021.
Online issue publication 
January 25, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.